Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments Academic Article uri icon

Overview

MeSH Major

  • Acetylmuramyl-Alanyl-Isoglutamine
  • Bone Neoplasms
  • Immunologic Factors
  • Neoplasm Recurrence, Local
  • Osteosarcoma
  • Phosphatidylethanolamines

abstract

  • Mifamurtide had a manageable safety profile; PK/PD of mifamurtide in this patient access study was consistent with prior studies. Two-year OS was 45.9%. A randomized clinical trial would be required to definitively determine impact on patient outcomes.

publication date

  • February 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4533988

Digital Object Identifier (DOI)

  • 10.1002/pbc.24686

PubMed ID

  • 23997016

Additional Document Info

start page

  • 238

end page

  • 44

volume

  • 61

number

  • 2